<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223443</url>
  </required_header>
  <id_info>
    <org_study_id>VELETI II</org_study_id>
    <nct_id>NCT01223443</nct_id>
  </id_info>
  <brief_title>Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents</brief_title>
  <acronym>VELETI II</acronym>
  <official_title>Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents as a New Approach to MainTaining VeIn Graft Patency and Reducing Cardiac Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Sealing moderate SVG lesions with paclitaxel-eluting stents reduces cardiac
      events (death, myocardial infarction, target vessel revascularization) over the duration of
      follow-up.

      Primary objective: To evaluate the efficacy of stenting moderate SVG lesions with
      paclitaxel-eluting stents on reducing the first occurrence of the composite of cardiac death,
      myocardial infarction or repeat revascularization related to the target SVG over the duration
      of follow-up (minimun of 2-year follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized study assessing the efficacy of stenting
      moderate SVG lesions (30% to 60% by visual estimation) with paclitaxel-eluting stents in the
      prevention of SVG atherosclerosis progression and cardiac events at follow-up. Patients with
      previous coronary bypass surgery with SVG implantation undergoing coronary angiography by
      clinical indication will be screened. If the patient has a moderate lesion at any level of
      the SVGs it will be includable in the study. After inclusion, the patients will be randomized
      to either stenting the moderate SVG lesion with the taxus stent or standard medical
      treatment. Following this procedure, all patients will have follow-up visits by telephone or
      clinic at 30 days, 180 days, 1 year, and yearly until the common study end date. The duration
      of the study will be approximately 4 years with a minimun of 2-year follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was prematurely stopped due to slow patient enrolment.
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The first occurrence of the composite of cardiac death, myocardial infarction or coronary revascularization related to the target SVG over the duration of follow-up.</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-First occurrence of the composite of cardiac death, myocardial infarction or coronary revascularization over the duration of follow-up.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-Cardiac death and myocardial infarction; repeat revascularization; and hospitalization due to an acute coronary syndrome.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-Total medical costs (at index hospitalization and at follow-up).</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Costs per major adverse cardiac event (cardiac death, myocardial infarction, revascularization) prevented.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-Severe (&gt;60%) SVG lesions or SVG occlusion at the target SVG at 2-year follow-up as determined by 3D computed-tomography.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-Major bleeding complications defined according to the REPLACE-II criteria over the duration of follow-up.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-Stent thrombosis defined and classified according to the Academic Research Consortium criteria.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Coronary Artery Bypass Grafting</condition>
  <arm_group>
    <arm_group_label>PCI-stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stenting the moderate SVG lesion with the paclitaxel stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard medical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel eluting stent</intervention_name>
    <description>Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment</description>
    <arm_group_label>PCI-stenting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical indication for cardiac catheterization and SVG angiography

          2. Presence of at least one SVG lesion of 30% to 60% diameter stenoses, by visual
             estimation, which is not the culprit lesion* responsible for the clinical syndrome of
             the patient

             *If the target lesion is located in the same SVG than the culprit lesion (if present)
             it has to be at least 4 cm far from the stented segment)

          3. Written informed consent

        Exclusion Criteria:

          1. Patient &lt; 18 years old

          2. Ejection fraction &lt; 30%

          3. Renal insufficiency with creatinine &gt; 200 μmol/l

          4. Presence of more than 2 moderate SVG stenoses in a single SVG or significant diffuse
             SVG disease defined as disease covering more than half of the length of the SVG

          5. Presence of more than 2 SVGs with moderate SVG stenoses

          6. Unsuccessful angioplasty (residual stenosis &gt;30% and/or TIMI flow &lt;3) of any other
             lesion treated during the same procedure (culprit lesions will be treated before
             patient randomization)

          7. Any significant complication occurring during the angioplasty of the culprit lesion(s)
             during the same procedure

          8. SVG lesion located at the distal anastomosis

          9. SVG lesions located at the proximal anastomosis (lesion length &lt; 5 mm from the SVG
             ostium)

         10. Lesion length &gt;25 mm

         11. SVGs ≤ 3 years ago

         12. Cardiogenic shock

         13. Remaining coronary or SVG lesion(s) with treatment (PCI or CABG) planned within the
             following year

         14. Pregnancy

         15. Contraindication to aspirin and/or thienopyridine/ticagrelor treatment

         16. Allergy to paclitaxel

         17. Any disease with a limiting life-expectancy (less than 2 years)

         18. Need for chronic anticoagulation treatment

         19. Definite presence or high suspicion of thrombus or ulceration in the target lesion

         20. Target lesion located in the same SVG as the culprit lesion (if present) and distance
             between the target lesion and the most proximal or distal part of the stent implanted
             at the culprit lesion &lt; 4 cm

         21. Vein graft diameter &lt; 2.5 mm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Rodes-Cabau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut universitaire de cardiologie et de pneumologie de Québec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Josep Rodes-Cabau</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Bypass Grafting</keyword>
  <keyword>Drug Eluting Stent</keyword>
  <keyword>Saphenous Vein Graft</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

